AB0540 INTERRELATION OF HYPERURICEMIA AND BURDEN OF COMORBIDITIES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Authors: E. Kornilova, V. Mazurov, A. Fonturenko, R. Bashkinov, O. Inamova, I. Gaydukova
Journal: Annals of the Rheumatic Diseases (2022)

Background Comorbidities play an important role in the course and prognosis of systemic lupus erythematosus (SLE) [1]. Hyperuricemia (HP) could cause an increased burden of comorbidities in SLE patients (pts). Objectives To evaluate the interrelation between HP and comorbidities in pts with SLE. Methods We performed retrospective analysis of the data from 191 SLE pts that were collected in electronic Saint-Petersburg rheumatological register in a period from 01 Jan 2009 until 31 Dec 2020. In analysis were involved data of 85 SLE patients with hyperuricemia (serum uric acid level &gt;360 µmol/l in 3 reports) (group 1) and of 106 SLE pts with normal uric acid level in 3 laboratory reports (≤360µmol/l) – group 2. Pts with rheumatological diseases other then SLE, with gout, active infections, oncological diseases, with glomerular filtration rate &lt;30 ml/min*1.73 m2 and other secondary reasons of HP were excluded. The clinical and laboratory data, presence of comorbidities, Charlson Comorbidity Index, SELENA-SLEDAI were analyzed. SPSS2020 was used to Statistics. Local ethics committee approved the study. Results SLE pts with and without HP were matched in age, sex and disease activity characteristics, Table 1(p≥0.05). Uric acids’ level did not correlate with activity of SLE (SELENA-SLEDAI), Spearmen’ r=0.06, p≥0.05. Hypertension, obesity, hypercholesterolemia, diabetes mellitus, lower renal function were more common in SLE patients with HP than in SLE patients without HP, Table 1. Charlson comorbidity index was higher in SLE pts of than in SLE pts without HP (p&lt;0.05). Table 1. Clinical characteristics and occurrence of comorbidities in SLE pts. Patients and Disease’ characteristics Group 1 (n=85) Group 2 (n=106) Р-value Age, years, mean ± SD 47.05±13.51 44.84±12.11 ≥0.05 Female, n (%) 69 (81.18) 95(89.62) ≥0.05 SELENA-SLEDAI, mean ± SD 7.33±5.03 6.15±3.92 ≥0.05 SLE duration, years, mean ± SD 4.73±5.01 0.97±2.15 &lt;0.05 Serum uric acid, µmol/l, mean ± SD 434.6±63.16 238.38±59.36 &lt;0.05 Нypertension, n (%) 52(61.18) 30(28.3) &lt;0.05 Obesity, n (%) 15(17.65) 5(4.72) &lt;0.05 Hypercholesterolemia, n (%) 54(63.53) 34(32.08) &lt;0.05 Diabetes mellitus, n (%) 14(16.47) 3(2.83) &lt;0.05 Glomerular filtration rate, ml/min*1.73 m 2 , mean ± SD 80.29±28.35 95.81±23.38 &lt;0.05 SD - standard deviation Conclusion Elevated serum uric acid levels in SLE patients are associated with a higher incidence of hypertension, hypercholesterolemia, obesity, diabetes mellitus, decreased glomerular filtration rate, with a higher Charlson comorbidity index, but not with disease activity. References [1]D. Apostolopoulos et all. DOI: 10.1136/lupus-2020-000436 Disclosure of Interests Elizaveta Kornilova: None declared, V Mazurov: None declared, Aleksandra Fonturenko: None declared, Roman Bashkinov: None declared, Oksana Inamova: None declared, Inna Gaydukova Speakers bureau: Novartis, Sandoz, Pfizer, Biocad, MSD, Dr Reddy’s, Lilly, Sanofy, not &gt;10000 Euros per year, Consultant of: Novartis, Pfizer, Biocad, MSD, Dr Reddy’s, Lilly, Sanofy, not &gt;10000 Euros per year, Grant/research support from: Novartis, Sandoz, Pfizer, Biocad, MSD, Dr Reddy’s, not &gt;10000 Euros per year